Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Xenogen (XGEN) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (17)	4/22/2005 5:28:20 PM
From: tuck	Read Replies (1) \| Respond to of 45

Lawsuit involves the following patents (Thanks, IJ!): patft.uspto.gov patft.uspto.gov patft.uspto.gov patft.uspto.gov patft.uspto.gov These are, indeed, the ones concerning metastatic disease imaging using GFP, the last being somewhat differently titled. As noted before (in post #15) several of these patents even reference a Contag/Stanford patent. It is my guess that this is the one that is up for re-examination. patft.uspto.gov I still think AntiCancer will have a difficult time with this case, looking at what prior art I can find. I'd love to get a second opinion. Again, since they don't seem to be selling many of their systems, AntiCancer has little to lose -- except legal fees -- even if their own patents here are ruled invalid. Xenogen has stated that path is part of their strategy in contesting this issue, and it seems a plausible outcome. Cheers, Tuck